The impact of COVID-19 on clinical outcomes among acute myocardial infarction patients undergoing early invasive treatment strategy.
COVID-19
cardiac catheterization
pediatric clinical cardiology
percutaneous coronary intervention
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
revised:
29
07
2022
received:
29
11
2021
accepted:
15
08
2022
pubmed:
31
8
2022
medline:
19
10
2022
entrez:
30
8
2022
Statut:
ppublish
Résumé
The implications of coronavirus disease 2019 (COVID-19) infection on outcomes after invasive therapeutic strategies among patients presenting with acute myocardial infarction (AMI) are not well studied. To assess the outcomes of COVID-19 patients presenting with AMI undergoing an early invasive treatment strategy. This study was a cross-sectional, retrospective analysis of the National COVID Cohort Collaborative database including all patients presenting with a recorded diagnosis of AMI (ST-elevation myocardial infarction (MI) and non-ST elevation MI). COVID-19 positive patients with AMI were stratified into one of four groups: (1a) patients who had a coronary angiogram with percutaneous coronary intervention (PCI) within 3 days of their AMI; (1b) PCI within 3 days of AMI with coronary artery bypass graft (CABG) within 30 days; (2a) coronary angiogram without PCI and without CABG within 30 days; and (2b) coronary angiogram with CABG within 30 days. The main outcomes were respiratory failure, cardiogenic shock, prolonged length of stay, rehospitalization, and death. There were 10 506 COVID-19 positive patients with a diagnosis of AMI. COVID-19 positive patients with PCI had 8.2 times higher odds of respiratory failure than COVID-19 negative patients (p = .001). The odds of prolonged length of stay were 1.7 times higher in COVID-19 patients who underwent PCI (p = .024) and 1.9 times higher in patients who underwent coronary angiogram followed by CABG (p = .001). These data demonstrate that COVID-19 positive patients with AMI undergoing early invasive coronary angiography had worse outcomes than COVID-19 negative patients.
Sections du résumé
BACKGROUND
BACKGROUND
The implications of coronavirus disease 2019 (COVID-19) infection on outcomes after invasive therapeutic strategies among patients presenting with acute myocardial infarction (AMI) are not well studied.
HYPOTHESIS
OBJECTIVE
To assess the outcomes of COVID-19 patients presenting with AMI undergoing an early invasive treatment strategy.
METHODS
METHODS
This study was a cross-sectional, retrospective analysis of the National COVID Cohort Collaborative database including all patients presenting with a recorded diagnosis of AMI (ST-elevation myocardial infarction (MI) and non-ST elevation MI). COVID-19 positive patients with AMI were stratified into one of four groups: (1a) patients who had a coronary angiogram with percutaneous coronary intervention (PCI) within 3 days of their AMI; (1b) PCI within 3 days of AMI with coronary artery bypass graft (CABG) within 30 days; (2a) coronary angiogram without PCI and without CABG within 30 days; and (2b) coronary angiogram with CABG within 30 days. The main outcomes were respiratory failure, cardiogenic shock, prolonged length of stay, rehospitalization, and death.
RESULTS
RESULTS
There were 10 506 COVID-19 positive patients with a diagnosis of AMI. COVID-19 positive patients with PCI had 8.2 times higher odds of respiratory failure than COVID-19 negative patients (p = .001). The odds of prolonged length of stay were 1.7 times higher in COVID-19 patients who underwent PCI (p = .024) and 1.9 times higher in patients who underwent coronary angiogram followed by CABG (p = .001).
CONCLUSION
CONCLUSIONS
These data demonstrate that COVID-19 positive patients with AMI undergoing early invasive coronary angiography had worse outcomes than COVID-19 negative patients.
Identifiants
pubmed: 36040721
doi: 10.1002/clc.23908
pmc: PMC9538930
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1070-1078Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL159945
Pays : United States
Organisme : NCATS NIH HHS
ID : U24 TR002306
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003015
Pays : United States
Organisme : NCATS NIH HHS
ID : NCATS U24 TR002306
Pays : United States
Informations de copyright
© 2022 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.
Références
Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-818.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
Mafham MM, Spata E, Goldacre R, et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020;396(10248):381-389.
Han H, Xie L, Liu R, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. J Med Virol. 2020;92(7):819-823.
Lala A, Johnson KW, Januzzi JL, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76(5):533-546.
Sandoval Y, Januzzi JL, Jr., Jaffe AS. Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week. J Am Coll Cardiol. 2020;76(10):1244-1258.
Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. N Engl J Med. 2019;380(2):171-176.
de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005;353(11):1095-1104.
Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2018;40(2):87-165.
Bennett TD, Moffitt RA, Hajagos JG, et al. Clinical characterization and prediction of clinical severity of SARS-CoV-2 infection among US adults using data from the US National COVID Cohort Collaborative. JAMA Netw Open. 2021;4(7):e2116901.
Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603-605.
Huang L, Zhao P, Tang D, et al. Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging. JACC Cardiovasc Imaging. 2020;13(11):2330-2339.
Clay CE, Sullivan AF, Bennett CL, Boggs KM, Espinola JA, Camargo CA Jr. The National COVID Cohort Collaborative: clinical characterization and early severity prediction. medRxiv. 2021;28:98-106.
Rodriguez F, Solomon N, de Lemos JA, et al. Racial and ethnic differences in presentation and outcomes for patients hospitalized with COVID-19: findings from the American Heart Association's COVID-19 cardiovascular disease registry. Circulation. 2021;143:2332-2342.
Garcia S, Dehghani P, Grines C, et al. Initial findings from the North American COVID-19 myocardial infarction registry. J Am Coll Cardiol. 2021;77(16):1994-2003.
Daniels MJ, Cohen MG, Bavry AA, Kumbhani DJ. Reperfusion of ST-segment-elevation myocardial infarction in the COVID-19 era: business as usual? Circulation. 2020;141(24):1948-1950.
Krittanawong C, Virk HUH, Narasimhan B, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular risk: a meta-analysis. Prog Cardiovasc Dis. 2020;63(4):527-528.
Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39(7):618-625.
Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185-192.
Kang Y, Chen T, Mui D, et al. Cardiovascular manifestations and treatment considerations in COVID-19. Heart. 2020;106(15):1132-1141.
Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265-1273.
Cardoso R, Rivera M, Czarny MJ, et al. In-hospital management and outcomes of patients with acute myocardial infarction and influenza. Am J Cardiol. 2020;125(6):840-844.
Vejpongsa P, Kitkungvan D, Madjid M, et al. Outcomes of acute myocardial infarction in patients with influenza and other viral respiratory infections. the. Am J Med. 2019;132(10):1173-1181.
Chew NWS, Ow ZGW, Teo VXY, et al. The global impact of the COVID-19 pandemic on STEMI care: a systematic review and meta-analysis. Can J Cardiol. 2021;37:1450-1459.
Dinnes J, Deeks JJ, Adriano A, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2020;8(8):Cd013705.
Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020;173(4):262-267.